26062-48-6

Usage

Uses

Used in Nanotechnology Industry:
Poly-L-histidine hydrochloride MW is used as a polycation for the dispersion of multi-wall carbon nanotubes (MWCNTs). Its cationic nature helps in the dispersion process, enhancing the properties and potential applications of MWCNTs in various fields.
Used in Virology Research:
Poly-L-histidine hydrochloride MW is used as a polyionic compound to investigate its ability to rupture extracellular enveloped virus membranes. This application is crucial in understanding the interactions between viruses and host cells, as well as in the development of antiviral strategies.
Used in Prion Disease Research:
Poly-L-histidine hydrochloride MW is used in screening its anti-prion activity in cell-based and in vivo anti-prion assays. This application is significant in the study of prion diseases, which are a group of neurodegenerative disorders, and in the development of potential treatments for these conditions.

Biochem/physiol Actions

Poly-L-histidine (Phis) copolymers are biocompatible, pH responsive and are less toxic. It exhibits endolysosomal escape funcationality. The copolymer of Phis with poly(ethylene glycol)?poly(d,l-lactide) (PEG-PLA) is effective in delivering doxorubicin. pH sensitive poly(l-histidine) copolymer micelles have application in delivering anticancer drugs in acidic microenvironment.

InChI:InChI=1/C6H9N3O2/c7-5(6(10)11)1-4-2-8-3-9-4/h2-3,5H,1,7H2,(H,8,9)(H,10,11)/t5-/m0/s1

Upstream product

• 71-00-1 L-histidine 
• 10101-30-1 N-acetylhistidine 
• 14056-33-8 2-(benzoylamino)-3-imidazol-4-ylpropanoic acid 
• 2497-02-1 N-acetyl-L-histidine 
• 645-35-2 L-histidine monohydrochloride 
• 4998-57-6 His 
• 58942-05-5 5-[(4-imidazolyl)methyl]hydantoin 
• 74419-67-3 2-Carboxy-L-histidine Hydrochloride 
• 1604-44-0 N-α-trifluoroacetyl-L-histidine methyl ester 
• 1499-46-3 L-histidine methyl ester 
• 108-24-7 acetic anhydride 
• 71-00-1 L-histidine 

Downstream Products

• 19728-57-5 C₁₄H₁₅N₃O₄ 
• 128424-98-6 C₁₅H₁₇N₇O₇ 
• 128425-10-5 C₁₅H₁₇N₇O₇ 
• 507-29-9 hercynine 
• 59981-63-4 (6S)-4,5,6,7-tetrahydro-1H-imidazo<4,5-c>pyridine-6-carboxylic acid 
• 14403-45-3 (S)-3-(5-imidazolyl)-2-hydroxypropionic acid 
• 3465-72-3 urocanic Acid 
• 1025939-62-1 H-L-His(Trt)-OH 
• 645-14-7 (3H-imidazol-4-yl)acetaldehyde 
• 22835-06-9 [2',4',2-3H3]-DL-His 
• 86541-64-2 (2S)-2-amino-3-(1H-imidazol-4-yl)-N-methylpropanamide 
• 69614-04-6 S-(+)-7-Methoxycarbonyl-5,6,7,8-tetrahydroimidazo<1,5-c>pyrimidin-5-on 

Relevant academic research and scientific papers

Facile Production of D-Histidine by Asymmetric Transformation of L-Histidine

An asymmetric transformation from L-histidine to D-His was achieved by using salicylaldehyde as a catalyst for epimerization, and (2R,3R)-tartaric acid as a resolving agent, in acetic acid.Treatment of the obtained salt with triethylamine in methanol gave D-His with 100percent optical purity in 95percent yield based on the starting L-His.

Reduction potential of histidine free radicals: A pulse radiolysis study

The technique of pulse radiolysis has been used to demonstrate that all histidine free radicals (designated His.+) produced by oxidation of histidine by Br2.- radical anions can oxidise the water soluble vitamin E analogue, Trolox C (k = 1.0 ± 0.2 × 109 dm3 mol-1 s-1 at pH 6.95). It has also been shown that His.+ radicals can react with tryptophan in electron transfer equilibria involving both His.+ and Trp.+ species over the pH range 6.4-9.0. The ΔE values [E(Trp.+/Trp) - E(His.+/His)] range from -140 to -161 mV and indicate an E7(His.+/His) value of 1170 mV [based on E7(Trp.+/Trp) = 1015 mV at pH 7]. The effect of pH on E(His.+/His) was accounted for by assuming that His.+ can deprotonate to yield a bi-allylic free radical, designated His (-H+).. The pKa for this dissociation was estimated to be in the range 5-7. The implications of the relatively high reduction potential for His.+ in its possible participation in the mechanism of action of non-heme metalloenzymes is discussed.

Preparation and characterization of a new open-tubular capillary column for enantioseparation by capillary electrochromatography

In order to use the enantioseparation capability of cationic cyclodextrin and to combine the advantages of capillary electrochromatography (CEC) with open-tubular (OT) column, in this study, a new OT-CEC, coated with cationic cyclodextrin (1-allylimidazolium-β-cyclodextrin [AI-β-CD]) as chiral stationary phase (CSP), was prepared and applied for enantioseparation. Synthesized AI-β-CD was characterized by infrared (IR) spectrometry and mass spectrometry (MS). The preparation conditions for the AI-β-CD-coated column were optimized with the orthogonal experiment design L9(34). The column prepared was characterized by scanning electron microscopy (SEM) and elemental analysis (EA). The results showed that the thickness of stationary phase in the inner surface of the AI-β-CD-coated columns was about 0.2 to 0.5?μm. The AI-β-CD content in stationary phase based on the EA was approximately 2.77?mmol·m?2. The AI-β-CD-coated columns could separate all 14 chiral compounds (histidine, lysine, arginine, glutamate, aspartic acid, cysteine, serine, valine, isoleucine, phenylalanine, salbutamol, atenolol, ibuprofen, and napropamide) successfully in the study and exhibit excellent reproducibility and stability. We propose that the column, coated with AI-β-CD, has a great potential for enantioseparation in OT-CEC.

Chromatographic Resolution of α-Amino Acids by (R)-(3,3'-Halogen Substituted-1,1'-binaphthyl)-20-crown-6 Stationary Phase in HPLC

Three new chiral stationary phases (CSPs) for high-performance liquid chromatography were prepared from R-(3,3'-halogen substituted-1,1'-binaphthyl)-20-crown-6 (halogen = Cl, Br and I). The experimental results showed that R-(3,3'-dibromo-1,1'-binaphthyl)-20-crown-6 (CSP-1) possesses more prominent enantioselectivity than the two other halogen-substituted crown ether derivatives. All twenty-one α-amino acids have different degrees of separation on R-(3,3'-dibromo-1,1'-binaphthyl)-20-crown-6-based CSP-1 at room temperature. The enantioselectivity of CSP-1 is also better than those of some commercial R-(1,1'-binaphthyl)-20-crown-6 derivatives. Both the separation factors (α) and the resolution (Rs) are better than those of commercial crown ether-based CSPs [CROWNPAK CR(+) from Daicel] under the same conditions for asparagine, threonine, proline, arginine, serine, histidine and valine, which cannot be separated by commercial CR(+). This study proves the commercial usefulness of the R-(3,3'-dibromo-1,1'-binaphthyl)-20-crown-6 chiral stationary phase.

Synthesis and antimicrobial activities of His(2-aryl)-Arg and Trp-His(2-aryl) classes of dipeptidomimetics

In this communication, we report the design, synthesis and in vitro antimicrobial activity of ultra short peptidomimetics. Besides producing promising antibacterial activities against Staphylococcus aureus and methicillin-resistant S. aureus (MRSA), the dipeptidomimetics exhibited high antifungal activity against C. neoformans with IC50 values in the range of 0.16-19 μg mL-1. The most potent analogs exhibited 4-fold higher activity than the currently used drug amphotericin B, with no apparent cytotoxicity in a panel of mammalian cell lines. This journal is the Partner Organisations 2014.

INSULIN PREPARATIONS CONTAINING METHIONINE

The invention relates to an aqueous pharmaceutical formulation having insulin, an insulin analog, or an insulin derivative, and methionine; and to the production thereof, to the use thereof for treating diabetes mellitus, and to a medication for treating diabetes mellitus.

ANTIBIOFILM GLYCOPEPTIDES

The present invention relates to peptides and compositions that have antibiofilm properties. In particular, the peptides and compositions of the invention can be used for the treatment or prevention of various conditions including dental caries, gingivitis, periodontitis, oral mucositis, dry mouth and xerostomia.

NOVEL INSULIN DERIVATIVES HAVING AN EXTREMELY DELAYED TIME-ACTION PROFILE

The invention relates to novel insulin analogs having a basal time-action profile, which are characterized by the following features: a) the B chain end consists of an amidated basic amino acid residue such as lysine or arginine amide; b) the N-terminal amino acid residue of the insulin A chain is a lysine or arginine radical; c) the amino acid position A8 is occupied by a histidine radical; d) the amino acid position A21 is occupied by a glycine radical; and e) one or more substitutions and/or additions of negatively charged amino acid residues are carried out in the positions A5, A15, A18, B-1, B0, B1, B2, B3 and B4.

AGENT FOR PREVENTING/TREATING CANCER

A human monoclonal antibody against a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 3, its partial peptide, or a salt thereof, is useful as an agent for preventing/treating cancer, etc., an apoptosis inducer of cancer cells, a growth inhibitor of cancer cells, a cytotoxic agent against cancer cells through a host defense mechanism mediated by the Fc region of an antibody, and so on.

Modulation of Glutamine Synthetase Activity

Methods of screening and designing compounds as inhibitors of glutamine synthetase are provided herein. Compounds, e.g., serine protease inhibitors, and compositions comprising the same, that are useful for the treatment, prevention, and/or amelioration of bacterial infections, including Mycobacterium tuberculosis, are also provided.